Breaking News

Isis Earns $1M GSK Milestone

June 24, 2014

Advances study of ISIS-TTRRx in patients with FAP

Isis Pharmaceuticals, Inc. has earned a $1 million milestone payment from GlaxoSmithKline for the advancement of the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). GSK is developing ISIS-TTRRx as a treatment for transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. 
 
To date, Isis has earned $26 million in upfront and milestone payments for advancing ISIS-TTRRx. If GSK exercises its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and royalties.
 
"We are very pleased with the progress we are making with ISIS-TTRRx.  In addition to being on schedule for enrollment, we have initiated an open-label extension study of ISIS-TTRRx, which is being offered to those patients with FAP who have completed dosing in the Phase II/III study of ISIS-TTRRx," said B. Lynne Parshall, chief operating officer at Isis.  

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.